Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma

BACKGROUND: Rabacfosadine (RAB, Tanovea‐CA1) is a novel chemotherapy agent conditionally approved for the treatment of lymphoma in dogs. HYPOTHESIS/OBJECTIVES: To determine the efficacy and safety of RAB in dogs with lymphoma. ANIMALS: One hundred and fifty‐eight client‐owned dogs with naïve or rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Weishaar, Kristen M., Wright, Zachary M., Rosenberg, Mona P., Post, Gerald S., McDaniel, Jennifer A., Clifford, Craig A., Phillips, Brenda S., Bergman, Philip J., Randall, Elissa K., Avery, Anne C., Thamm, Douglas H., Christman Hull, Abigail A., Gust, Cathy M., Donoghue, Ann R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
SMALL ANIMAL
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783351/
https://www.ncbi.nlm.nih.gov/pubmed/34952995
http://dx.doi.org/10.1111/jvim.16341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783351/
https://www.ncbi.nlm.nih.gov/pubmed/34952995
http://dx.doi.org/10.1111/jvim.16341

Ejemplares similares